COOKIES USE We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics. +info
Cookies config
Necessary
The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_GRECAPTCHA
google.com
Own
provide antispam protection with the reCaptcha service
6 months
cc_cookie_accept
fidmag.org
Own
Usada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)
1 any
WEB_SESSION
fidmag.org
Own
Cookie técnica: cookie de sessió PHP. Guarda l'id de sessió d'usuari.
al acabar la sessió
Analisys
Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_ga
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics
2 anys
_gat_gtag_UA_141706552_1
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Tracking per part de google per google analytics
1 minut
_gid
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds
Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
Pacchiarotti I, Tiihonen J, Kotzalidis GD, Verdolini N, Murru A, Goikolea JM, Valentí M, Aedo A, Vieta E
Limited service to collaborators of the network of Sisters Hospitalarias Centers. You will receive a message in your email with a link to download this article.
Abstract
Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance in psychoses, mainly schizophrenia spectrum disorders. We aimed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder (BD) and/or Schizoaffective Disorder (SAD). We searched six databases from inception to 28-March-2018, using the strategy: long-acting antipsychotics AND (bipolar disorder OR schizoaffective disorder OR mania OR manic OR bipolar depression). We included peer-reviewed double-blind comparisons of LAIs for any clinical outcome occurrence in BD, or open mirror studies with same prospective as retrospective assessment periods. We excluded studies reporting on mixed schizophrenia/SAD populations without reporting results separately. The pooled records amounted to 642. After duplicate removal and inclusion/exclusion criteria application, we included 15 studies, 6 double-blind and 9 open, 13 assessing BD and 2 SAD. Depot neuroleptics prevented manic, but not depressive recurrences and may worsen depressive symptoms. Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo, but not from depressive recurrences. Add-on or monotherapy paliperidone palmitate in SAD patients protected from psychotic, depressive, and manic symptoms. In patients with BD-I with a manic episode at study enrolment, aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes. LAIs are effective and well-tolerated maintenance treatments for BD and SAD. They showed better efficacy in preventing mania than depression. LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems.